Major Pharma Got a Major Win Last Night - BMO
Get Alerts ABBV Hot Sheet
Rating Summary:
20 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
BMO Capital analyst Alex Arfaei said a Trump presidency, Republican controlled congress, and apparent defeat of CA Prop 61 as significantly positive developments for major Pharma because they should lead to:
1) lower drug pricing pressure in the U.S.,
2) potential repeal of Obamacare with more industry friendly reforms,
3) increased probability for lower corporate tax rates, and profit repatriation, which should in turn lead to increased capital returned to shareholders and more M&A.
"We see the news as positive for our entire coverage universe, particularly for PFE (NYSE: PFE)," he said.
Other Stocks:
AbbVie (NYSE: ABBV)
Bristol-Myers Squibb (NYSE: BMY)
Kindred Biosciences (NASDAQ: KIN)
Eli Lilly & Co. (NYSE: LLY)
Merck (NYSE: MRK)
Zoetis (NYSE: ZTS)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
- Mizuho on Intel (INTC): "Just when you thought it could not get any worse..."
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Trader TalkRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!